Zur Rose concludes rights issue
Frauenfeld – The online pharmacy Zur Rose has successfully concluded the rights issue with its capital increase. The proceeds will finance an acquisition and further growth measures.
Zur Rose initiated a capital increase to finance its acquisition of the German mail order pharmacy Medpex and further organic growth measures. Following shareholder approval around ten days ago, the online pharmacy from the St.GallenBodenseeArea has now successfully concluded the rights issue, according to a statement.
A total of 889,239 new shares were issued to existing shareholders, while 1,261,299 new shares were placed with investors during the international offering. This brings the total of new shares sold to some 2.15 million, each with a fixed asking price of 93 Swiss francs. The new registered shares will be traded for the first time on Monday 3 December on the SIX Swiss Exchange.
The Medpex acquisition will be completed via Zur Rose’s German subsidiary DocMorris. As the “Deutsche Apotheker Zeitung” reported, the German Competition Authority has approved the acquisition.